The Oncology Institute, Inc.
TOI
$0.716
$0.09114.56%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 378.93M | 361.07M | 342.71M | 324.24M | 309.88M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 378.93M | 361.07M | 342.71M | 324.24M | 309.88M |
| Cost of Revenue | 325.19M | 305.72M | 285.27M | 264.67M | 249.05M |
| Gross Profit | 53.74M | 55.35M | 57.44M | 59.57M | 60.82M |
| SG&A Expenses | 111.17M | 112.69M | 113.49M | 113.87M | 115.94M |
| Depreciation & Amortization | 6.16M | 6.28M | 6.09M | 5.87M | 5.49M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 442.52M | 424.69M | 404.85M | 384.41M | 370.48M |
| Operating Income | -63.59M | -63.62M | -62.14M | -60.17M | -60.60M |
| Income Before Tax | -70.55M | -71.72M | -73.04M | -83.10M | -75.41M |
| Income Tax Expenses | -314.00K | -179.00K | -80.00K | -36.00K | -89.00K |
| Earnings from Continuing Operations | -70.24 | -71.54 | -72.96 | -83.07 | -75.32 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -70.24M | -71.54M | -72.96M | -83.07M | -75.32M |
| EBIT | -63.59M | -63.62M | -62.14M | -60.17M | -60.60M |
| EBITDA | -57.43M | -57.34M | -56.05M | -54.29M | -55.11M |
| EPS Basic | -0.77 | -0.79 | -0.81 | -0.92 | -0.83 |
| Normalized Basic EPS | -0.60 | -0.61 | -0.62 | -0.57 | -0.47 |
| EPS Diluted | -0.78 | -0.80 | -0.82 | -0.93 | -0.92 |
| Normalized Diluted EPS | -0.60 | -0.61 | -0.62 | -0.57 | -0.47 |
| Average Basic Shares Outstanding | 297.98M | 295.92M | 295.29M | 294.51M | 293.79M |
| Average Diluted Shares Outstanding | 297.98M | 295.92M | 295.29M | 294.51M | 293.79M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
